Abstract
Objectives: While providing medication abortion in primary care has the potential to expand abortion access and decrease stigma, provision of this care is still largely limited to specialized reproductive health clinics. Family physicians are well-positioned to provide medication abortions given their geographic distribution and long-term relationships with patients but face logistical, institutional, and other structural barriers. Our multidisciplinary research team conducted a qualitative study to understand how communications messaging and strategies could be leveraged to encourage family physicians to overcome these barriers.
Highlights
This study aims to assess the preferred terminology among people presenting for abortions and to explore the pregnancy characteristics associated with these preferences
Participants who felt very worried other people might find out about the abortion, compared to participants who were not at all worried, were more likely to prefer “ending a pregnancy” over no preference for a term. These findings indicate that people have varied preferences for how they want to refer to their abortions, emphasizing the importance of being responsive to people’s preferences during clinical interactions and in the design and conduct of abortion research
We evaluated the sociodemographic and service use characteristics for cases managed by a regional abortion fund in the US Southeast for callers ages 21 and under
Summary
Compare induction to delivery intervals and complications in second trimester labor induction using mifepristone with misoprostol vs misoprostol alone. Methods: A retrospective analysis was performed of second trimester induction terminations at two urban medical centers over ten years. Inclusion criteria were pregnancies between 14.0 weeks and 23.6 weeks gestation without evidence of labor, intrauterine infection, or ruptured membranes upon admission. Comparisons between mifepristone plus misoprostol or misoprostol alone were performed, including composite complications (retained placenta requiring surgery, infection, hemorrhage, blood transfusion, failed induction, ICU admission, and readmission), total misoprostol dosage, and induction to delivery intervals. Results: The final analysis included 406 patients, 286 (66%) at gestational age > 20 weeks. Most were for fetal anomalies (196, 48.3%) or intrauterine fetal demise (199, 49.0%). Thirty-two percent (n=133) received mifepristone plus misoprostol and sixty-seven percent (n= 273) received misoprostol alone
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
